Eli Lilly's TuneLab, which the company describes as its first-of-its-kind artificial intelligence initiative, has reached 100 members, according to Endpoints News. The milestone was paired with news that the program is adding AI models from Chai to its lineup.
The basic idea behind TuneLab is unusual for a large drugmaker. According to Endpoints News, Lilly was trying something new by effectively offering biotechs free access to some of its AI capabilities. In an industry where computational tools and data are closely guarded competitive assets, handing smaller companies a way to tap into a pharmaceutical giant's AI resources is a notable departure from the norm.
Endpoints News reports that the leader behind TuneLab had no idea what to expect when the initiative launched. Reaching 100 members suggests the experiment has found real demand among biotech firms, which often lack the scale, budgets, and in-house data to build advanced AI tools on their own.
The addition of Chai's models signals that TuneLab is continuing to broaden what participants can use, rather than remaining a static, one-time offering. Expanding the catalog of available AI tools makes the program more useful to a wider range of members working on different scientific problems.
Details beyond these points were not provided in the source material, so it is not yet clear from the reporting exactly how members use the tools or what Lilly ultimately gains from the arrangement.
Why it matters: If a major drugmaker can successfully share AI tools with smaller biotechs at no cost, it could reshape how cutting-edge drug-discovery technology spreads across the industry — potentially speeding up research at companies that otherwise could not afford it.